Rhumbline Advisers Has $29.19 Million Position in Penumbra, Inc. (NYSE:PEN)

Rhumbline Advisers lessened its stake in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 1.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,147 shares of the company's stock after selling 1,239 shares during the quarter. Rhumbline Advisers owned 0.28% of Penumbra worth $29,187,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hurley Capital LLC bought a new position in shares of Penumbra during the 4th quarter worth approximately $56,000. Huntington National Bank raised its position in Penumbra by 138.7% in the 4th quarter. Huntington National Bank now owns 265 shares of the company's stock valued at $63,000 after purchasing an additional 154 shares during the last quarter. Mather Group LLC. raised its position in Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company's stock valued at $73,000 after purchasing an additional 208 shares during the last quarter. Versant Capital Management Inc raised its position in Penumbra by 893.5% in the 1st quarter. Versant Capital Management Inc now owns 308 shares of the company's stock valued at $82,000 after purchasing an additional 277 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its position in Penumbra by 25.0% in the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock valued at $89,000 after purchasing an additional 75 shares during the last quarter. Institutional investors own 88.88% of the company's stock.

Penumbra Trading Up 0.2%

Shares of Penumbra stock traded up $0.45 during trading on Friday, reaching $258.83. 376,022 shares of the company were exchanged, compared to its average volume of 448,567. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The business has a 50-day moving average price of $276.89 and a 200-day moving average price of $267.10. The firm has a market capitalization of $10.02 billion, a price-to-earnings ratio of 761.26, a P/E/G ratio of 2.83 and a beta of 0.49.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The business had revenue of $324.14 million during the quarter, compared to analysts' expectations of $315.72 million. During the same period in the previous year, the firm earned $0.41 earnings per share. The firm's quarterly revenue was up 16.3% compared to the same quarter last year. Sell-side analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Bank of America assumed coverage on Penumbra in a research report on Friday, March 14th. They issued a "buy" rating and a $320.00 price objective for the company. Wall Street Zen downgraded Penumbra from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th. JPMorgan Chase & Co. lifted their price objective on Penumbra from $230.00 to $285.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. BTIG Research reiterated a "buy" rating on shares of Penumbra in a research report on Thursday, April 24th. Finally, Robert W. Baird lifted their price objective on Penumbra from $316.00 to $325.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Penumbra currently has an average rating of "Moderate Buy" and an average target price of $302.40.

Insider Buying and Selling at Penumbra

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $300.01, for a total value of $180,006.00. Following the completion of the transaction, the executive vice president now directly owns 66,159 shares of the company's stock, valued at approximately $19,848,361.59. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Adam Elsesser sold 16,300 shares of the business's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $267.91, for a total value of $4,366,933.00. Following the completion of the transaction, the chief executive officer now directly owns 98,289 shares of the company's stock, valued at approximately $26,332,605.99. The trade was a 14.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 128,845 shares of company stock valued at $36,359,981. Company insiders own 4.20% of the company's stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.